SEC Tracker
Get the app

Jazz Pharmaceuticals JAZZ

Jazz Pharmaceuticals reports Q3 IPR&D charge

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Estimated pre-tax IPR&D charge of $755 million
  2. Impact of $11.00 per share on GAAP and non-GAAP EPS
  3. Acquisition of Actio Biosciences completed on Sept 15, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Jazz Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Repligen RGEN public float $6.0B, Jun 30, 2025
  3. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.